Vigil Neuroscience
Founded Year
2020Stage
IPO | IPOTotal Raised
$140MDate of IPO
1/7/2022Market Cap
0.32BStock Price
8.88About Vigil Neuroscience
Vigil Neuroscience (NASDAQ: VIGL) is a microglia-focused therapeutics company. Vigil Neuroscience aims to treat rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system.
Missing: Vigil Neuroscience's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Vigil Neuroscience's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Vigil Neuroscience
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Vigil Neuroscience is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Vigil Neuroscience Patents
Vigil Neuroscience has filed 3 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Transcription factors
- ABC transporters
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
5/4/2021 | Application |
Application Date | 5/4/2021 |
|---|---|
Grant Date | |
Title | |
Related Topics | |
Status | Application |
Latest Vigil Neuroscience News
Dec 16, 2022
Bionomics (NASDAQ: BNOX ) has appointed Spyridon "Spyros" Papapetropoulos, M.D. Spyros, most recently served as the Chief Medical Officer of Vigil Neuroscience Inc, a Nasdaq-listed biopharmaceutical company developing a pipeline of neuroimmune targeted therapeutics for the treatment of neurodegenerative disorders. Errol B. De Souza, Ph.D., who has been serving as Bionomics' Executive Chairman since November 2018, will continue in his role through 31 December 2022 to ensure a seamless transition, and will resume the role of Non-Executive Chairman of the board effective 1 January 2023. In consequence of the timing of the appointment and transition arrangements, Dr. De Souza will continue to be entitled to compensation arrangements in line with those under his existing employment contract until 30 June 2023. Recommended For You
Vigil Neuroscience Frequently Asked Questions (FAQ)
When was Vigil Neuroscience founded?
Vigil Neuroscience was founded in 2020.
Where is Vigil Neuroscience's headquarters?
Vigil Neuroscience's headquarters is located at One Broadway, Suite 07-300, Cambridge.
What is Vigil Neuroscience's latest funding round?
Vigil Neuroscience's latest funding round is IPO.
How much did Vigil Neuroscience raise?
Vigil Neuroscience raised a total of $140M.
Who are the investors of Vigil Neuroscience?
Investors of Vigil Neuroscience include Northpond Ventures, Atlas Venture, Hatteras Venture, Pivotal bioVenture Partners, OrbiMed Advisors and 11 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.